Agitation Associated With Bipolar Mania — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for agitation associated with bipolar mania. 270 active patents protecting 2 drugs from 2+ originators. First major cliff: 2031. Daily refresh.

2
Approved drugs
270
Active US patents
63/100
Avg vulnerability
$3.3B
Annual revenue covered

Originators in Agitation Associated With Bipolar Mania

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Generic (originally Otsuka/BMS) 214 patents Eli Lilly 56 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating agitation associated with bipolar mania. Each bar = one year. Y-axis scaled to peak year (54 patents).

20
26
21
27
6
28
54
29
48
30
48
31
10
32
37
33
8
34
3
40

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Abilify
aripiprazole
 Generic (originally Otsuka/BMS) 214 61 $3.0B 2026-07-28
Zyprexa
olanzapine
 Eli Lilly 56 64 $300M 2031-08-23

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
12194035 Zyprexa method of use 81 2031-08-23

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9119848 Zyprexa composition of matter 10 2031-08-30
9119848 Zyprexa composition of matter 10 2031-08-30
9119848 Zyprexa composition of matter 10 2031-08-30
9119848 Zyprexa composition of matter 10 2031-08-30
10517507 Abilify formulation 42 2032-06-13
10517507 Abilify formulation 42 2032-06-13
10517507 Abilify formulation 42 2032-06-13
10517507 Abilify formulation 42 2032-06-13
10517507 Abilify formulation 42 2032-06-13
10517507 Abilify formulation 42 2032-06-13

Related